EP Wealth Advisors LLC Acquires New Position in United Therapeutics Corporation $UTHR

EP Wealth Advisors LLC bought a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, Holdings Channel reports. The fund bought 1,044 shares of the biotechnology company’s stock, valued at approximately $566,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Leuthold Group LLC increased its stake in shares of United Therapeutics by 41.4% in the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after purchasing an additional 3,126 shares in the last quarter. UBS Group AG lifted its stake in shares of United Therapeutics by 45.3% during the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after buying an additional 70,445 shares in the last quarter. Nicholas Investment Partners LP boosted its holdings in United Therapeutics by 478.5% in the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock worth $2,218,000 after buying an additional 3,766 shares during the period. M&T Bank Corp boosted its holdings in United Therapeutics by 171.6% in the 4th quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock worth $1,531,000 after buying an additional 1,985 shares during the period. Finally, Seven Fleet Capital Management LP purchased a new stake in United Therapeutics in the 4th quarter worth $633,000. Institutional investors own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the sale, the executive vice president owned 45,172 shares in the company, valued at approximately $23,631,280.08. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $518.39, for a total transaction of $4,924,705.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $168,188,006.77. The trade was a 2.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 434,075 shares of company stock worth $233,942,595 over the last ninety days. Insiders own 8.60% of the company’s stock.

United Therapeutics Trading Down 0.0%

Shares of UTHR stock opened at $512.88 on Tuesday. United Therapeutics Corporation has a 12-month low of $302.19 and a 12-month high of $609.35. The stock’s 50-day moving average price is $532.35 and its 200-day moving average price is $538.04. The stock has a market capitalization of $22.00 billion, a price-to-earnings ratio of 18.35, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm’s revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the company earned $6.41 earnings per share. As a group, research analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on UTHR shares. Royal Bank Of Canada decreased their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. JPMorgan Chase & Co. boosted their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.